60 Degrees Pharmaceuticals Inc (SXTP)
60 Degrees Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for the prevention and treatment of infectious diseases in the United States. Its commercial product includes Arakoda, which is used for malaria prevention. The company is also advancing several development programs, including Tafenoquine for potential use in COVID-19, babesiosis, fungal pneumonias, and candidiasis, as well as Celgosivir for Zika, respiratory viruses, and dengue. In addition, 60 Degrees Pharmaceuticals has a patent license agreement with Tufts Medical Center to support joint development and commercialization efforts for tafenoquine in babesiosis. Founded in 2010, the company is headquartered in Washington, District of Columbia.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SXTP
|
—
|
—
|
—
|
$3.70
|
140.3% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
November 14, 2025
|
—
|
—
|
—
|
4.016 M
|
—
|
—
|
90.8%
|
—
|
—
|
—
|
